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Abstract
The podocyte is a key cell in the selective ﬁltering action of the glomerular capillary wall. Podo-
cyte injury is of pathogenetic and prognostic signiﬁcance in human glomerular disease; podocyte
repair and regeneration are important therapeutic targets. In particular, podocyte function is de-
pendent on the cells’ actin cytoskeleton: this maintains their complex structure. Alterations in the
actin cytoskeleton arise from a variety of genetic and acquired causes. Therapeutic agents that
are beneﬁcial in proteinuric disease may act at least partly by restoring the cell shape via effects
on the actin cytoskeleton. Recent studies of podocytes in vivo and in vitro are described, high-
lighting clinically relevant observations and those that help us understand the ways in which we
may harness nature’s own mechanisms to repair and/or renew these specialized glomerular cells,
with a particular focus on their actin cytoskeleton. Drugs that have beneﬁcial effects on podo-
cytes can improve our ability to treat important renal diseases including diabetic nephropathy.
Currently available agents can be applied in this way and the rapid progress in the study of podo-
cytes is highlighting new therapeutic targets that can bring even more speciﬁcity.
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Introduction
A clinical nephrology readership needs no convincing of
the importance of proteinuria: it has prognostic signiﬁ-
cance in patients with a wide variety of forms of renal
disease and is a potent independent cardiovascular risk
factor [1]. In health, proteinuria is prevented by the selec-
tive ﬁltering action of the glomerular capillary wall. This
has a tripartite structure comprising podocytes (visceral
glomerular epithelial cells) on the outer (urinary) aspect,
fenestrated glomerular endothelial cells on the inner
(luminal) aspect and the highly negatively charged glo-
merular basement membrane lying between the two cell
types. It should be stated at the outset that each of
these three components exerts an important inﬂuence
on the selective permeability of the glomerular capillary
wall and it is a mistake to think of any of the components
in isolation. Nevertheless, much of the focus in recent
years has been on the podocyte and its actin cytoskele-
ton: these will be the focus of this article and I will
attempt to highlight the clinical and therapeutic rel-
evance of recent advances in the understanding of their
cellular and molecular biology.
Podocyte injury and repair are relevant to the diverse
forms of renal disease, including major clinical problems
such as diabetic nephropathy [2], but many of the key
principles are illustrated by focal segmental glomerulo-
sclerosis (FSGS), a common and important cause of ne-
phrotic syndrome. It is now generally accepted that the
predominant glomerular lesion in FSGS is an injury to
podocytes [3]. FSGS is one of the most difﬁcult renal dis-
eases to manage, with a real possibility that the cumulat-
ive toxicity of the various agents used in treatment has
the potential to make the therapy as bad as or worse
than the disease. Although our drugs are often effective
in controlling the nephrotic state, we have all seen
patients whose physical appearance, bones, skin, glucose
tolerance, etc. have been wrecked by long-term treat-
ment with corticosteroids or whose kidney function has
been damaged by calcineurin inhibitor toxicity. We ur-
gently need more speciﬁc agents: there is accumulating
evidence that the podocyte is the appropriate cellular
target [4], and in particular, agents that stabilize the
actin cytoskeleton are likely to be beneﬁcial.
Podocytes: cells of great beauty
Podocytes imaged by scanning electron microscopy are,
in the opinion of this author, aesthetically very pleasing
(Figure 1). They have a cell body, long primary processes
and a complex network of interdigitating secondary pro-
cesses. This complex cellular architecture is maintained
by a precise organization of microtubules and actin ﬁla-
ments in the cellular cytoplasm.
Transmission electron microscopic imaging will be
more familiar to nephrologists from looking at real biop-
sies and shows that the normal glomerular capillary wall,
on the urinary side, has a series of ﬁltration slits between
the foot processes of the podocytes (Figure 2a). It has
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been known for decades that a cardinal feature of the
glomerular capillary wall in proteinuric states is ﬂattening
or effacement of the foot processes due to disruption of
this precise organization. The key to understanding the
importance of the actin cytoskeleton is the demon-
stration (Figure 2b) that this effacement of foot processes
is associated with ﬂattening of the actin ﬁlaments.
In recent years, it has become ever clearer that the
precise organization and regulation of the actin cytoske-
leton in the podocyte are essential for the maintenance
of its normal structure and function, that disruption
thereof is a feature of podocyte diseases and is associ-
ated with proteinuria, and perhaps most importantly of
all that therapeutic agents which have beneﬁcial effects
in nephrotic syndrome are capable of restoring the podo-
cyte actin cytoskeleton.
Podocytes’ actin cytoskeleton: insights
from genetic conditions
Many of the recent advances in the understanding of po-
docyte biology have come from studies of rare inherited
forms of nephrotic syndrome which have been found to
be due to mutations in podocyte genes (reviewed in [5]).
One example with particular relevance to the importance
of the actin cytoskeleton concerns the gene encoding
alpha-actinin IV, which plays an important role in actin
polymerization. Elegant work from Martin Pollak’s group
showed that mutations in alpha-actinin IV were associ-
ated with autosomal dominant late-onset familial FSGS
[6] and that the mutant form of the protein binds more
avidly to actin and affects the mechanical properties of
actin gels, providing an explanation for its effect on the
podocyte structure [7]. Another group then showed that
podocyte-speciﬁc transgenic expression of the mutant
alpha-actinin IV gene in mice leads to FSGS [8], demon-
strating that it is the effects of the gene in the podocyte
rather than any other cell that is responsible for the
disease. The ﬁnal proof of the causative role of the
mutation came in experiments in which Pollak’s group
showed that, when the mutant gene was ‘knocked-in’ in
mice, the animals developed FSGS, showing that this
gene defect alone is capable of causing the disease [9].
The mechanisms underlying the effects of the mutant
protein have now been demonstrated in detail [10].
Pollak’s group have provided further evidence that the
physicochemical characteristics of actin ﬁbres formed
with the mutant alpha-actinin IV show altered ﬂexibility
that can explain the effects on the podocyte [11]. Most
recently, the alpha-actinin IV protein mutants have been
shown to mislocalize to the cell cytoplasm and lose their
ability to associate with nuclear receptors and activate
gene transcription [12]. Other groups have reported
different gene mutations which affect the actin cytoske-
leton and also cause FSGS: for instance, in the gene en-
coding CD2-associated protein which encodes a protein
that is important in linking to actin ﬁbres [13].
What about acquired forms of proteinuric
disease?
Clinical nephrologists will inevitably ask whether these
rare genetic forms of FSGS are analogous to the much
more common sporadic forms of the disease. Shared
mechanisms are likely to exist: for example, in relation to
the glomerular disease associated with human immuno-
deﬁciency virus (HIV) in which podocytes are speciﬁcally
targeted by the virus, a key HIV protein called Nef inter-
acts with actin and alters the shape of podocytes [14].
Does the actin cytoskeleton play a similar role in idio-
pathic FSGS? We do not yet know for sure, but recent
observations on the mechanisms of action of drugs
which are effective in FSGS have caused real excitement
and shown the way to more speciﬁc forms of treatment.
Calcineurin inhibitors, especially cyclosporin, are widely
used in the treatment of proteinuric diseases including
FSGS; their use originally being based on the assumption
that the diseases are immune-mediated and that, there-
fore, the immunosuppressive effects of such drugs are
likely to be helpful. Faul et al. [15] made the novel obser-
vation that the anti-proteinuric effects of cyclosporin can
be explained by direct effects on the podocyte actin cy-
toskeleton (and therefore the cell’s shape) and are
Fig. 2. Transmission electron micrographs of the human glomerular
capillary wall. (a) shows the normal appearance: arrows indicate
endothelial fenestrations, arrowheads indicate ﬁltration slits between
podocyte foot processes and asterisks indicate actin ﬁlaments in
podocyte cytoplasm. Note the actin ﬁlaments focused in podocyte foot
processes. (b) shows podocyte foot process effacement as seen in
proteinuric states: note ﬂattening of the actin ﬁlaments (asterisked)
longitudinally associated with the loss of normal foot process
architecture.
Fig. 1. Scanning electron micrograph of podocytes on urinary aspect of
normal glomerular capillary showing: (a) cell bodies, (b) primary
processes and (c) interdigitating secondary processes that form ﬁltration
slits resembling the teeth of a zipper.
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independent of its effects on T lymphocytes. The mech-
anism involves synaptopodin, a key stabilizer of the actin
cytoskeleton in podocytes. When synaptopodin is phos-
phorylated, it is protected from degradation. Calcineurin
(which is blocked by cyclosporin) dephosphorylates sy-
naptopodin and allows its degradation. Thus, cyclosporin
prevents the degradation of synaptopodin, stabilizes the
actin cytoskeleton and protects against proteinuria. This
suggests that nephrologists have been using the right
drugs for the wrong reason [16]. This suggestion is
further supported by analysis of the effects of corticoster-
oids, widely used in nephrotic syndrome, without us
having much idea how they work [16]. Dexamethasone is
the corticosteroid usually studied in vitro because it is not
a pro-drug: it has potent effects on human podocytes in-
cluding on their size and shape [17] and has recently
been shown to interact with alpha-actinin IV in stabilizing
the podocyte actin cytoskeleton and protecting it from
the injurious effects of adriamycin [18]. Many of the
effects of dexamethasone on podocytes can be mi-
micked by another currently available form of therapy,
thiazolidinediones (‘glitazones’) [19] and this may help us
explain the anti-proteinuric effects of this group of drugs.
What about novel, more speciﬁc forms
of therapy?
The fact that many of the treatments that we currently
use have potent effects on podocytes is of great interest,
but clearly these agents are non-speciﬁc and have many
unwanted effects. If we are to bring beneﬁts to our
patients from the recent scientiﬁc advances, we need to
develop more speciﬁc therapeutic approaches. One
pathway that can be selectively targeted by drugs is the
system of small GTPase proteins of the Rho family. Acti-
vation of RhoA in podocytes induces FSGS [20] with dis-
ruption of the actin cytoskeleton [21]. Rho-kinase
inhibition protected podocytes and reduced proteinuria in
one mouse model [22]. There is still some controversy
about which protein forms the most logical target, with
another recent paper suggesting that RhoA is not the key
member of the family in podocytes, instead providing evi-
dence that another Rho family GTPase, cdc42, is the key
one for maintenance of the podocyte actin cytoskeleton
[23]. A protein which is activated by RhoA, Arhgap24, has
also been suggested as a downstream target since this
molecule is important in the maintenance of normal po-
docyte shape and a gene mutation in the ARHGAP24
gene was found in a family with FSGS [24]. Rho kinase
inhibitors are already available for therapeutic use and
should be tested in humans for their effectiveness in pro-
teinuric disease. Other promising targets with protective
effects on the podocyte actin cytoskeleton, and for which
therapeutic agents are already available, include block-
ade of the tumour necrosis factor alpha pathway [25],
and stimulation of the calcium-sensing receptor [26].
Finally, just to reiterate that podocytes are not the
whole story: glomerular endothelial cells also depend for
their integrity on an actin cytoskeleton, and this too is
regulated by Rho-kinases [27]. Disease situations such as
diabetes mellitus are likely to affect both glomerular cell
types, and in thinking about novel therapeutic ap-
proaches, as we strive for greater speciﬁcity we need to
remember that we may need to target more than one
cell type.
Conclusions
The shape and structural complexity of podocytes
underlie their function, and when disrupted lead to pro-
teinuria. The actin cytoskeleton is a dynamic, highly regu-
lated intracellular scaffold that maintains this shape and
is disrupted in genetic (and probably also in acquired)
forms of the nephrotic syndrome. Currently used thera-
pies undoubtedly have effects on podocytes and this
may explain some or all of their usefulness in some
forms of glomerular disease. Other currently available
therapies, as yet untested in proteinuric diseases, may
have great potential. New pathways are being identiﬁed
in glomerular cells that may provide even better thera-
peutic targets in future. Watch this space!
Points of interest
(i) Podocytes are structurally and functionally complex
cells which play a key role in the normal prevention
of proteinuria
(ii) In many renal diseases, including FSGS and diabetic
nephropathy, podocyte injury/loss is a major patho-
genetic and prognostic factor
(iii) The actin cytoskeleton in podocytes is responsible for
the maintenance of their shape and their function
(iv) Podocyte foot process effacement is associated with
major alterations in the actin cytoskeleton
(v) Currently used therapies including steroids and cy-
closporin have direct effects on the podocyte actin
cytoskeleton
(vi) Our ever-improving knowledge of glomerular cell
biology in health and disease will allow new more
speciﬁc forms of therapy to be developed
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